COTA Featured in OncLive – Data Analytics Making Inroads Into Oncology Practices
Around this growing interest and adoption, COTA’s chief medical officer, Dr. C.K. Wang, recently spoke with OncLive about how COTA’s Real World Analytics platform helps cancer centers correlate care patterns with outcomes.
COTA’s Mike Doyle Reflects on COVID-19 as a CEO & Health Data Veteran
In two recent articles, COTA CEO Mike Doyle reflects on how the pandemic is challenging leaders to be flexible and, specifically in healthcare, how data companies can be doing more.
Does Using RWE in COVID-19 Research Eliminate the Barrier of Time? Two Data Scientists Explain
To further explain COTA’s in-depth analysis and research methods from this ongoing work, Kathryn Tanenbaum, Senior Manager of Operations at COTA spoke with two of our data experts leading COTA’s analysis, Eric Hansen, director of analytics, and Shivam Mathura, director of product and strategy.
COTA Supports FDA Assessment of Real-World Data through Membership in COVID-19 Evidence Accelerator
Leveraging its past knowledge of real-world evidence applications and learnings, COTA has joined the COVID-19 Evidence Accelerator program, a joint initiative of Friends of Cancer Research (Friends) and the Reagan-Udall Foundation for the Food and Drug Administration. Through this initiative, COTA is delivering findings from its observational, real-world studies using data from over 3,000 patients hospitalized with COVID-19 within the Hackensack Meridian Health network.
Real-World Evidence Provides Insights Into the Effectiveness of Hydroxychloroquine and Tocilizumab for Treating COVID-19 – New Findings Published
COTA, in collaboration with Hackensack Meridian Health and Berry Consultants, recently conducted a study using real-world data from more than 3,000 patients hospitalized with COVID-19. The study concluded hydroxychloroquine does not improve survival for patients hospitalized with COVID-19. It was also found that another drug, tocilizumab, may improve survival among critically ill intensive care unit patients.
COTA, Inc. Announces Participation in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program and DIA 2020 Virtual Global Annual Meeting
COTA, Inc., is pleased to announce its involvement and participation in two industry leading conferences – the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program and the DIA 2020 Virtual Global Annual Meeting. Collectively, the involvement at these two premier events further underscores the importance of RWD’s role in clinical research and oncology care delivery.
2020 MedTech Breakthrough Awards Recognize COTA as the Best Overall Medical Data Solution Provider
COTA, Inc. is pleased to announce that MedTech Breakthrough has named COTA as a winner in the fourth annual MedTech Breakthrough Awards program for the “Best Overall Medical Data Solution Provider” award.
COTA Participates in Reagan-Udall Foundation + Friends of Cancer Research COVID-19 Evidence Accelerator
COTA is actively participating in this collaboration, presenting key findings from ongoing research with Hackensack-Meridian Health involving observational, real-world studies of more than 3,000 hospitalized COVID-19 patients.
Celebrating the Nurses at COTA During National Nurses Week
In recognition of National Nurses Week, we’ve asked COTA’s nurses a few questions about their motivation for becoming a nurse, how their current roles in healthcare technology differs from their experience working in the hospital, and their message to nurses currently on the frontlines of the pandemic.
COTA Collaborates to Understand COVID-19 Using Real-World Evidence – New Findings Published
COTA has partnered with Hackensack Meridian Health (HMH), New Jersey’s largest and most comprehensive health network, and Berry Consultants to conduct an observational real world study of more than 3,000 hospitalized COVID-19 patients.
